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Abstract
Background: In animal models ghrelin reduces cardiac afterload and increases cardiac output via receptors in the cardiovascular system.
The aim of our study was to evaluate a potential relationship between weight loss treatment, blood pressure and serum ghrelin concentra-
tions in obese women.
Material and methods: A group of 37 obese premenopausal women with no previous history of hypertension (BMI: 36.5 ± 5 kg/m2) were
involved in the study. Blood pressure and serum ghrelin levels were assessed before and after a three-month weight reduction treatment,
which consisted of a diet of 1000 kcal/day and physical exercise. Body composition was determined by impedance analysis using Bodystat.
Results: Following weight loss (mean 8.9 ± 4.8 kg) SBP decreased (120 ± 13 vs. 115 ± 14 mm Hg, p = 0.01) and serum ghrelin levels
increased significantly (66.9 ± 13.7 vs. 73.9 ± 15.4 pg/ml; p = 0.005). There were significant correlations between values for ghrelin levels
after weight loss and SBP (r = –0.45, p = 0.02), DBP (r = –0.41, p < 0.05), and between Dghrelin levels and DSBP (r = 0.52, p = 0.006), DDBP
(r = 0.53, p = 0.005). There was a positive correlation between an increase in ghrelin and a decrease in percentage body fat during weight
loss (r = 0.51; p = 0.002).
Conclusion: The results seem to provide evidence that weight loss may decrease blood pressure in obese patients via a ghrelin-dependent
mechanism. (Pol J Endocrinol 2008; 59 (3): 207–211)
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Streszczenie
Wstęp: W modelach zwierzęcych grelina powoduje zmniejszenie obciążenia następczego serca i zwiększenie rzutu serca poprzez wpływ
na receptory znajdujące się w układzie sercowo-naczyniowym. Celem badania było określenie zależności między redukcją masy ciała,
ciśnieniem tętniczym a stężeniem greliny w surowicy u kobiet z otyłoscią.
Materiał i metody: Badaniem objęto 37 otyłych kobiet (wskaźnik masy ciała [BMI, body mass index] 36,5 ± 5 kg/m2) bez nadciśnienia
tętniczego w wywiadzie. Ciśnienie tętnicze i stężenie greliny w surowicy oznaczono przed i po 3-miesiecznej kuracji odchudzającej, która
obejmowała dietę 1000 kcal/d. i ćwiczenia fizyczne. Skład ciała określono metodą analizy impedancji z użyciem aparatu Bodystat.
Wyniki: W następstwie redukcji masy ciała (średnio 8,9 ± 4,8 kg) nastąpiło istotne obniżenie SBP (120 ± 13 vs. 115 ± 14 mm Hg, p = 0,01)
i zwiększenie stężenia greliny w surowicy (66,9 ± 13,7 vs. 73,9 ± 15,4 pg/ml; p = 0,005). Stwierdzono istotne korelacje między stężeniami
greliny po redukcji masy ciała a SBP (r = –0,45, p = 0,02) i DBP (r = –0,41, p = 0,05) oraz między Dstężeń greliny a DSBP (r = 0,52, p = 0,006),
DDBP (r = 0,53, p = 0,005). Wykazano dodatnią korelację między wzrostem stężenia greliny a zmniejszeniem procentowej zawartości
tłuszczu w organizmie pod wpływem terapii odchudzającej (r = 0,51, p = 0,002).
Wnioski: Wyniki badania dowodzą, że zmniejszenie masy ciała może spowodować obniżenie ciśnienia tętniczego u osób otyłych przez
mechanizm zależny od greliny. (Endokrynol Pol 2008; 59 (3): 207–211)
Słowa kluczowe: otyłość, grelina, ciśnienie tętnicze, zmniejszenie masy ciała
Introduction
Ghrelin is a growth hormone-releasing peptide isola-
ted from the stomach and is involved in the pathoge-
nesis of obesity. It exerts anabolic effects through growth
hormone (GH) stimulation and a direct positive energy
balance. Ghrelin secretion is probably up-regulated
under conditions of a negative energy balance and
down-regulated in the setting of a positive energy ba-
lance [1–3].
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Moreover, ghrelin is a new peptide modulating cen-
tral sympathetic activity [4], a function which would
seem to be of importance, because changes in the auto-
nomic function have been implicated in the develop-
ment and progress of obesity and its complications, in-
cluding systemic hypertension [5].
Recent data indicate that ghrelin may also have be-
neficial haemodynamic effects. It has been demonstra-
ted that ghrelin reduces cardiac afterload and increases
cardiac output via receptors in the cardiovascular sys-
tem [6]. This is not accompanied by an increase in heart
rate. Experimental study has shown that ghrelin inhi-
bits vascular superoxide production in spontaneously
hypertensive rats. This effect is probably related to the
inhibition of vascular NAD(P)H oxidases [7].
The results obtained by Mager et al. [8] revealed that
several ghrelin gene variations were associated with
blood pressure levels in subjects with impaired glucose
tolerance.
On the basis of the data, we would like to put for-
ward a novel and perhaps interesting hypothesis that
weight loss may decrease blood pressure in hyperten-
sive patients via a ghrelin-dependent mechanism.
The aim of our study was to evaluate a potential re-
lationship between weight loss treatment, blood pres-
sure and serum ghrelin concentrations in obese women.
Material and methods
The examinations were carried out on 37 premenopau-
sal women with simple obesity and no previous histo-
ry of hypertension (mean age 40.7 ± 11.0 years; mean
body weight 96.7 ± 17.2 kg; mean body mass index
(BMI) 36.5 ± 5.0 kg/m2). Possible secondary causes for
obesity were ruled out on the basis of case history, phy-
sical examination, and laboratory tests, including de-
termination of glucose and hormone levels. Mean va-
lues of blood pressure ranged from systolic blood pres-
sure (SBP) 119.6 ± 13.3 mm Hg, diastolic blood pressu-
re (DBP) 80.0 ± 11.9 mm Hg. Subjective and objective
(12-lead ECG and sonocardiography) examinations did
not reveal any pathology within the cardiovascular sys-
tems of the obese patients.
In obese patients the examination, which included
blood pressure and body composition, was carried out
twice: before and after an effective three-month weight
reduction treatment, which comprised a low-calorie diet
(1000 kcal) with water and vitamin supplementation,
constant daily sodium and potassium intake, and phy-
sical exercise. Additionally group instruction in beha-
vioural and dietary methods of weight control was car-
ried out every two weeks. Body composition was de-
termined by impedance analysis (Bodystat).
The exclusion criteria included evidence of present
or recent (preceding 3 months) infectious disease, fe-
ver, and drug therapy. The study was approved by the
local ethical committee. All subjects gave their informed
consent to their participation in the study.
The determination of ghrelin in the blood serum was
carried out by enzyme-linked immunosorbent assay
with Phoenix Pharmaceuticals kits. The sensitivity of
ghrelin assay was less than 6.0 pg/ml. Intra- and inte-
rassay coefficients of variations (CV) were < 5.4%, and
< 6.0% respectively. The measurements of insulin serum
concentrations were performed by the RIA method (DPC
Diagnostic Products Corporation, Los Angeles, USA).
Insulin resistance was assessed on the basis of fa-
sting serum concentrations of glucose and insulin. The
HOMA index was calculated by the formula: HOMA =
= fasting serum concentration of insulin (mIU/ml) × fa-
sting serum concentration of glucose (mmol/l)/ 22.5. The
normal HOMA range is < 2.77 [9].
Samples of 6–8 ml of venous blood were collected
from each subject after an overnight fast. After clot for-
mation the samples were centrifuged (1000 g) at room
temperature for 10 minutes. The serum obtained was
drawn into a few plastic vials, and stored at –80°C until
the time of assay.
Statistical analysis
Each variable was checked for normality of distribution
by the Kolmogorov-Smirnov test. Within-group com-
parisons were made by a paired t test for regular data
distribution, and by the Wilcoxon signed-rank test for
non-normal data distribution. Values are presented as
mean ± SD. Pearson’s rank correlation test was applied
to assess correlations between the parameters exami-
ned. Stepwise multivariate analysis was performed with
serum levels of ghrelin, Dghrelin, BMI and DBMI, body
fat and Dbody fat, free fat mass and Dfree fat mass as
the independent variables and DSBP and DDBP as the
dependent variables.
Differences were considered statistically significant
at p < 0.05.
Results
A three-month weight reduction treatment, which al-
lowed for 8.9 ± 4.8 kg weight loss, resulted in a signifi-
cant decrease in BMI values (36.5 ± 5.4 kg/m2, 33.4 ±
± 5.2 kg/m2, respectively) and changes in body compo-
sition assessed by the impedance method (Table I).
Heart rate slowed down as compared to baseline
values (76.6 ± 3.0 vs. 71.2 ± 2.4 bpm, p = 0.05). Post-
treatment SBP was significantly lower than pre-treatment
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values (p = 0.01). There were no differences between
baseline and post-treatment DBP values (Table II).
Mean serum ghrelin concentrations significantly
increased after the three-month weight reduction tre-
atment (66.9 ± 13.7 vs. 73.9 ± 15.4 pg/ml; p = 0.005).
The serum insulin concentration and HOMA index value
were comparable before and after follow-up (Table III).
Pre-treatment correlations
Statistical analysis of the baseline parameters revealed
no correlation between ghrelin levels and the clinical
data assessed.
Insulin levels and HOMA index values correlated
positively with weight (r = 0.43, p = 0.02 and r = 0.45,
p = 0.01 respectively), and BMI (r = 0.42, p = 0.03;
r = 0.45, p = 0.02).
The baseline SBP correlated with age (r = 0.47, p < 0.01),
BMI (r = 0.55, p < 0.005), and body composition indi-
ces. The baseline DBP correlated with BMI (r = 0.45,
p < 0.05) and body composition indices (Table IV).
Post-treatment correlations
The analysis of post-treatment data revealed that SBP
correlated negatively with ghrelin levels (r = –0.45;
p < 0.05) and positively with insulin levels and HOMA
index value (r = 0.44, p = 0.02; r = 0.47; p = 0.03 re-
spectively). Similar to the baseline findings, the post-
treatment SBP also correlated with age (r = 0.48, p < 0.01),
BMI (r = 0.52; p < 0.005) and indices of body composi-
tion (Table V).
There were also significant correlations between
DBP and ghrelin (r = –0.41, p < 0.05) and insulin levels
and HOMA index value (r = 0.45, p < 0.05; r = 0.51,
p < 0.01 respectively). Additionally, DBP correlated with
BMI (r = 0.49, p < 0.01) and FFM (r = –0.46, p < 0.05).
There were significant correlations between post-
weight loss values of ghrelin levels and SBP (r = –0.45,
p < 0.05), DBP (r = –0.41, p < 0.05), and between Dghre-
lin levels and DSBP (r = 0.52, p = 0.006), DDBP (r = 0.53,
p = 0.005). There was a positive correlation between an
increase in ghrelin and a decrease in body fat percenta-
ge during weight loss (r = 0.51; p = 0.002).
A stepwise multivariate regression analysis using
DSBP and DDBP as dependent variables was also per-
formed. The DSBP was related positively to Dghrelin
(r = 0.26; F = 11.55; p = 0.001) and Dbody fat (kg)
(r = 0.23; F = 14.57; p = 0.002). The DDBP was related
positively to Dghrelin (r = 0.28; F = 10.56; p = 0.002)
and Dbody fat (kg) (r = 0.28; F = 16.67; p = 0.003).
Discussion
Literature data and our previous observations suggest that
ghrelin may be regarded as a new challenge in clinical rese-
arch on metabolic syndrome [1–3, 10]. Moreover, there are
some data that indicate that ghrelin may exert positive
haemodynamic effects, both central and peripheral [6].
The present study evaluates potential relationships
between the concentrations of ghrelin and the blood
Table I. Patient characteristics
Tabela I. Charakterystyka chorych
Pre-treatment Post-treatment p
Body mass [kg]  96.7±17.2 87.9±15.7 0.001
BMI [kg/m2]  36.5±5.4  33.4±5.2 0.001
FFM [kg]  53.8±6.9  51.5±6.8 0.05
FFM (%)  56.4±7.9  59.3±5.9 0.01
Fat tissue [kg] 42.2±13.6 35.6±10.6 0.001
Fat tissue (%)  43.2±7.9  40.3±6.0 0.01
BMI — body mass index; FFM — fat-free mass
Table II. Mean heart rate and blood pressure
Tabela II. Średnie wartości częstości rytmu serca i ciśnienia
tętniczego
Pre-treatment Post-treatment p
HR [bpm] 76.6±3.0 71.2±2.4 0.05
SBP [mm Hg] 119.6±13.3 114.8±13.8 0.01
DBP [mm Hg]  80.0±11.9 77.4±9.7 NS
HR — heart rate; SBP — systolic blood pressure; DBP — diastolic blood
pressure
Table III. Mean ghrelin and insulin serum concentrations
Tabela III. Średnie stężenia greliny i insuliny w surowicy
Pre-treatment Post-treatment p
Ghrelin [pg/ml] 66.9±13.7 73.9±15.4 0.005
Insulin [uUI/ml] 15.7±7.2 14.4±10.5 NS
Glucose [mmol/l] 4.8±0.4 5.1±0.5 NS
HOMA 3.8±0.2 3.4±0.2 NS
Table IV. Pre-treatment correlations of SBP and DBP
Tabela IV. Korelacje miedzy SBP i DBP przed terapią
Age BMI Fat tissue FFM
SBP r = 0.47** r = 0.55*** r = 0.59**** r = –0.57***
DBP r = 0.45* r = 0.47* r = –0.58***
SBP — systolic blood pressure; DBP — diastolic blood pressure,
* p < 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.001
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pressure values in obese women undergoing complex
obesity treatment. At the enrolment we observed no
correlation between the above-discussed parameters.
However, following weight loss treatment significant
negative correlations were noted between ghrelin se-
rum levels and SBP, DBP values. We did not find any
similar reports in the literature.
A variety of evidence seems to suggest that ghrelin
participates not only in feeding behaviour but also in
cardiovascular and sympathetic regulation. By central
nervous system mechanisms ghrelin suppresses sym-
pathetic activity and decreases blood pressure. Further-
more, it modulates heart rate and baroreflex control of
renal sympathetic nerve activity [11].
In animal models a decrease in arterial pressure witho-
ut a change in heart rate has been observed following intra-
venous ghrelin administration [12]. Similar to our findings,
a negative correlation was revealed by Makino et al. [13]
between plasma ghrelin concentration and SBP in normal
pregnant women. However, they observed that higher le-
vels of ghrelin in pregnant women induced hypertension
in comparison with those of normal pregnant women. Re-
cently Poykko et al. [14] revealed that ghrelin was indepen-
dently associated with type 2 diabetes, insulin concentra-
tion and elevated blood pressure. They measured fasting
plasma ghrelin levels in a large sample of the middle-aged
population and concluded that low ghrelin levels constitu-
ted a risk factor for diabetes and hypertension.
Finally, it is unclear what mechanism, whether va-
scular, myocardial or both, may be responsible for the
ghrelin haemodynamic effects observed in our study.
Taking into account the literature data [6], we may specu-
late that if ghrelin is acting to decrease afterload it could
decrease blood pressure. Secondly, if ghrelin suppresses
sympathetic activity and decreases heart rate it could de-
crease blood pressure. However, from the cardiac output
increase it could exert the opposite results too.
The results of other studies further clarify the role
of ghrelin in obesity development. Ghrelin is inversely
related to fasting insulin levels as well as waist-hip-
-ratio, a useful index of central obesity [14, 15]. Further-
more, there are studies supporting the concept that
basal ghrelin levels are directly related to insulin sensi-
tivity; these are suppressed in obesity, which is gene-
rally associated with increased insulin resistance [15].
The results of our study seem to be in accordance with
the above-mentioned data. The observed decrease of
blood pressure after weight loss may also be a result of
the increase in ghrelin levels.
Parallel to studies on obesity, those on anorexia ne-
rvosa confirm the hypothesis that ghrelin secretion is
regulated by energy balance. Shiiya et al. [2] found ele-
vated ghrelin levels in patients with anorexia nervosa
(i.e. with a negative energy balance) when compared to
those of healthy subjects.
Interesting findings were also reported in patients
with cardiac cachexia. Nagaya et al. [16, 17] found si-
gnificant correlations between ghrelin, GH, and tumo-
ur necrosis factor a (a positive correlation), and BMI
(a negative correlation). Changes in ghrelin concentra-
tions were related to body mass in cachectic patients,
and an increase in ghrelin levels was observed follo-
wing cachexia development. The results suggest that
not only absolute value of fat mass but also progressive
weight loss may influence plasma ghrelin levels.
The above reports are in accordance with our obse-
rvations that weight loss in obese subjects results in an
increase in ghrelin levels. Considering the fact that ac-
tivation of the ghrelin-GH axis exerts anabolic effects,
we suggest that the elevation of ghrelin levels after
weight loss may constitute a secondary, counter-regu-
latory mechanism preventing further weight loss.
In summary, an increase in ghrelin levels after we-
ight loss might be responsible for the haemodynamic
effects of weight reduction treatment. The results of our
study suggest that weight loss may also decrease blood
pressure in obese patients by a ghrelin-dependent me-
chanism. This constitutes a novel aspect of the study.
Conclusion
The results seem to form evidence that weight loss may
decrease blood pressure in obese patients via a ghrelin-
dependent mechanism.
Table V. Post-treatment correlations of SBP and DBP
Tabela V. Korelacje między SBP i DBP po terapii
Age BMI Fat tissue  FFM Insulin Ghrelin
SBP r = 0.48** r = 0.52*** r = 0.39* r = –0.64**** r = 0.44* r = –0.45*
DBP r = 0.49** r = –0.46* r = 0.45* r = –0.41*
SBP — systolic blood pressure; DBP — diastolic blood pressure, * p < 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.001
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